FATE
Fate Therapeutics Inc.
$1.35
+$0.06(+4.65%)
45
Overall
60
Value
41
Tech
36
Quality
Market Cap
$110.98M
Volume
1.55M
52W Range
$0.66 - $3.50
Target Price
$4.45
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $2.4M | $4.4M | $4.1M | $4.7M | $10.7M | $31.4M | $55.8M | $96.3M | $63.5M | $13.6M | ||
| Total Revenue | $2.4M | $4.4M | $4.1M | $4.7M | $10.7M | $31.4M | $55.8M | $96.3M | $63.5M | $13.6M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $2.4M | $4.4M | $4.1M | $4.7M | $10.7M | $31.4M | $55.8M | $96.3M | $63.5M | $13.6M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-30.2M | $-36.4M | $-46.2M | $-71.8M | $111.4M | $159.5M | $272.8M | $404.7M | $254.0M | $223.9M | ||
| Research & Development | $19.9M | $26.5M | $34.4M | $56.0M | $87.8M | $125.6M | $215.5M | $320.5M | $172.6M | $135.0M | ||
| Research Expense | $19.9M | $26.5M | $34.4M | $56.0M | $87.8M | $125.6M | $215.5M | $320.5M | $172.6M | $135.0M | ||
| Selling, General & Administrative | $10.4M | $9.9M | $11.9M | $15.8M | $23.6M | $33.9M | $57.3M | $84.2M | $81.4M | $74.2M | ||
| General & Administrative Expenses | $10.4M | $9.9M | $11.9M | $15.8M | $23.6M | $33.9M | $57.3M | $84.2M | $81.4M | $74.2M | ||
| Salaries & Wages | $-2.4M | $-3.2M | $-3.6M | $-6.3M | -- | -- | -- | -- | $43.5M | $41.5M | ||
| Depreciation & Amortization | $-687.0K | $-881.0K | $-971.0K | $-1.2M | $2.2M | $3.1M | $5.8M | $13.8M | $18.3M | $19.0M | ||
| Depreciation & Amortization | $-687.0K | $-881.0K | $-971.0K | $-1.2M | $2.2M | $3.1M | $5.8M | $13.8M | $18.3M | $19.0M | ||
| Other Operating Expenses | $-30.2M | $-36.4M | $-46.2M | $-71.8M | $-3.2M | $-1.8M | $-17.6M | $-9.1M | $-9.7M | $-10.3M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-27.8M | $-32.0M | $-42.1M | $-67.1M | $-100.7M | $-128.1M | $-217.0M | $-308.4M | $-190.5M | $-210.3M | ||
| EBITDA | $-26.9M | $-30.8M | $-40.6M | $-64.0M | $-94.6M | $-125.0M | $-211.1M | $-294.6M | $-147.5M | $-175.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $2.2M | $1.6M | $1.3M | $1.7M | $1.8M | -- | -- | -- | -- | -- | ||
| Intinc | $10.0K | $138.0K | $559.0K | $2.2M | $4.3M | $2.4M | $1.3M | $5.8M | $17.2M | $17.3M | ||
| Net Non-Operating Interest Income/Expense | $-2.2M | $-1.5M | $-709.0K | $494.0K | $2.6M | $2.4M | $1.3M | $5.8M | $17.2M | $17.3M | ||
| Other Income/Expense | -- | -- | $118.0K | -- | -- | $47.7M | $-3.5M | $20.8M | $-9.9M | $8.8M | ||
| Other Special Charges | -- | -- | $-118.0K | -- | -- | $-47.7M | $3.5M | $20.8M | $9.9M | $5.9M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-13.4M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $13.4M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-27.8M | $-31.8M | $-41.7M | $-64.9M | $-96.4M | $-128.1M | $-217.0M | $-308.4M | $-165.8M | $-194.7M | ||
| Pre-Tax Income | $-30.0M | $-33.5M | $-43.0M | $-66.6M | $-98.1M | $-173.4M | $-212.2M | $-281.7M | $-163.4M | $-186.3M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-2.2M | $2.1M | $-46.0K | $-304.0K | $-2.1M | $-1.3M | $-7.0M | $-11.1M | $-4.9M | $-8.4M | ||
| NET INCOME | ||||||||||||
| Net Income | $-30.0M | $-33.5M | $-43.0M | $-66.6M | $-98.1M | $-173.4M | $-212.2M | $-281.7M | $-160.9M | $-186.3M | ||
| Net Income (Continuing Operations) | $-30.0M | $-33.5M | $-43.0M | $-66.6M | $-98.1M | $-173.4M | $-212.2M | $-281.7M | $-160.9M | $-186.3M | ||
| Net Income (Discontinued Operations) | $-30.0M | $-33.5M | $-43.0M | $-66.6M | $-98.1M | $-173.4M | $-212.2M | $-281.7M | $-160.9M | $-186.3M | ||
| Net Income (Common Stockholders) | $-30.0M | $-33.5M | $-43.0M | $-66.6M | $-98.1M | $-173.4M | $-212.2M | $-281.7M | $-160.9M | $-186.3M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-219.1M | -- | -- | $-167.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-30.2M | $-36.4M | $-46.2M | $-71.8M | $111.4M | $159.5M | $272.8M | $404.7M | $254.0M | $223.9M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $25.5M | $31.8M | $42.0M | $56.2M | $68.2M | $82.4M | $94.7M | $96.8M | $98.4M | $113.7M | ||
| Average Shares Outstanding (Diluted) | $25.4M | $31.9M | $42.1M | $56.0M | $68.2M | $82.4M | $94.7M | $96.8M | $98.4M | $113.7M | ||
| Shares Outstanding | $57.7M | $82.8M | $105.5M | $130.0M | $151.9M | $93.8M | $96.4M | $98.2M | $99.2M | $114.6M | ||
| Basic EPS | -- | -- | -- | -- | $-1.44 | $-2.1 | $-2.24 | $-2.91 | $-1.64 | $-1.64 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-1.44 | $-2.1 | $-2.24 | $-2.91 | $-1.64 | $-1.64 | ||
| Diluted EPS | $-1.18 | $-1.05 | $-1.02 | $-1.19 | $-1.44 | $-2.1 | $-2.24 | $-2.91 | $-1.64 | $-1.64 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-2.91 | $-1.64 | $-1.64 | ||
| OTHER METRICS | ||||||||||||
| Other Gand A | $10.4M | $9.9M | $11.9M | $15.8M | $23.6M | $33.9M | $57.3M | $84.2M | $81.4M | $74.2M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $14.7M | ||
| Rent And Landing Fees | $10.4M | $9.9M | $11.9M | $15.8M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FATE | $1.35 | +4.7% | 1.55M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |